Pfizer and Biontech have started a clinical trial for a vaccine for Omicron, a novel mutation for COVID-19, on the 25th local time.
The clinical trial subjects are 1,420, who will be divided into three groups to participate in the clinical trial.
The first group is 600 people who have received the existing COVID-19 vaccine 90 to 180 days before the start of the clinical trial, and they will receive 1-2 doses of the Omicron vaccine.
The second group is about 600 people who have received a booster vaccination with the existing vaccine, and will receive the conventional vaccine or vaccine for Omicron.
The third group is 200 people who have not yet been vaccinated against COVID-19 and who have not yet contracted COVID-19, who will receive 3 doses of the vaccine for Omicron.
“This study is an academic approach to develop a long-acting vaccine while preventing Omicron at the same level as other mutations,” said Ugur Sahin, CEO of BioNTech.
He explained that the current vaccine also provides a high degree of protection against severe conversion following Omicron infection.
